Peptide Plugs
20 mg vial
- Vendor score
- 88/100
- Effective vial price
- Not available
- Effective price per mg
- Not available
ORView VendorPepGrades currently earns nothing from these vendor links.Purchase link pending destination approval.
Vesugen is a short-peptide product commonly placed in the bioregulator category.
Also known as vesugen
Historical market context
Historical market low and median per mg across recorded offers. These market summaries are separate from our exact-product comparisons.
History updated Sep 21, 2026. Vendor coverage, package sizes, product forms and promotions can vary over time. Use exact-product comparisons for current listed prices; historical market prices do not establish vendor trust.
| Date | Low /mg | Median /mg | Vendors | Offers |
|---|---|---|---|---|
| $1.51 | $2.68 | 11 | 14 | |
| $1.51 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.68 | 11 | 14 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.68 | $2.65 | 10 | 13 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.68 | 9 | 12 | |
| $1.89 | $2.70 | 8 | 11 | |
| $1.89 | $2.70 | 8 | 11 | |
| $1.89 | $2.60 | 7 | 10 | |
| $1.89 | $2.85 | 7 | 10 | |
| $1.89 | $2.85 | 7 | 10 | |
| $1.89 | $2.70 | 6 | 9 | |
| $1.89 | $2.47 | 5 | 8 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.22 | 4 | 7 | |
| $1.89 | $2.22 | 4 | 7 | |
| $1.89 | $2.17 | 3 | 6 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.25 | 4 | 7 | |
| $1.89 | $2.17 | 3 | 6 | |
| $1.89 | $2.17 | 3 | 6 | |
| $1.89 | $2.17 | 3 | 6 | |
| $1.89 | $2.17 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.80 | $2.06 | 3 | 6 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $1.89 | $2.10 | 2 | 5 | |
| $3.10 | $3.10 | 1 | 1 | |
| $3.10 | $3.10 | 1 | 1 | |
| $3.10 | $3.10 | 1 | 1 | |
| $3.10 | $3.10 | 1 | 1 | |
| $3.10 | $3.10 | 1 | 1 |
Research shortlist · Sep 12, 2026
These research selections use the same basis: 20 mg vial. The selections remain from Sep 12, 2026; each price below comes from its dated market observation.
20 mg vial
20 mg vial
20 mg vial
What it is
Vesugen is a short-peptide product commonly placed in the bioregulator category.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
No registered human trial was identified under this exact name in the current review. Published work may be preclinical or indexed under another name.
Search indexed research for this compound ↗Market context
Vesugen is commonly sold or discussed for organ-specific bioregulator research and general wellness goals. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
1 of 1 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| Peptide PlugsVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Oros ResearchVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Core PeptidesVendor grade | Grade B+ | 1 | 1 | $6320 mg vial · compare →Observed Sep 21, 2026 | View → |
| Biolongevity LabsVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Royal PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| PeptidologyVendor grade | Grade C | Not available | Not available | Not availableNo market observation | View → |
| Oath ResearchVendor grade | Grade C | Not available | Not available | Not availableNo market observation | View → |
| AIO PeptidesNot enough information to grade | Not enough information to grade | 1 | 1 | $51.20Automatic percent off · listed $6420 mg vial · compare →Observed Sep 21, 2026 | View → |
| Nuscience PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Peptides 4 ResearchNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.